Books.org participates in affiliate programs including Bookshop.org and the Amazon Services LLC Associates Program. We may earn a commission from qualifying purchases made through links on this page, at no additional cost to you.
Overview
A comprehensive survey of the latest therapeutic drug discoveries in cardiac and cardiovascular medicine and of the most recent breakthroughs in molecular cardiology. The authors describe the most advanced procedures in cardiac pharmacology today, including in vivo and in vitro whole animal studies, the electrophysiological methods used to study in pacemaker cells, and the application of biochemical principles and technologies to novel therapeutic agents. Also discussed are the methods used to express the ion channels involved in cardiovascular pharmacology, adenoviral vector delivery for cardiovascular gene therapy, pharmacometrics in cardiovascular drug development, gender differences in heart failure, and angiogenesis therapies for coronary heart disease.
Synopsis
Shaped by editor Pugsely (pharmacology, Forest Research Institute, New Jersey), 20 contributions from medical researchers, clinicians, and pharmacologists (most from the US; some from Canada and Europe) survey recent advances in molecular cardiology and review drug discoveries in cardiac and cardiovascular medicine. The volume integrates basic and clinical cardiac pharmacology by combining both classical and molecular aspects of therapeutic drug development. Specific attention is given to novel molecular targets, functional endpoints for evaluation, and clinical aspects of drug development. Annotation ©2003 Book News, Inc., Portland, OR
Doody Review Services
Reviewer:Thomas L. Pazdernik, PhD(University of Kansas Medical Center)
Description:This is a specialty book written by experts in the field of cardiac drug development as a contribution to the Methods in Pharmacology and Toxicology series.
Purpose:The purpose of this volume is to integrate basic and clinical cardiac pharmacology into one book that brings together both classical and molecular aspects in the development of drugs that affect the cardiovascular system.
Audience:This book provides a comprehensive overview of many advanced procedures in cardiac pharmacology that should be useful for graduate students and academic scientists as well as researchers in the pharmaceutical and biotechnology drug industries.
Features:The first section is an introductory overview of cardiac drug development from animal models to clinical trials written by the volume editor. The second section has chapters that deal with novel molecular targets as candidates for drug development, including oxygen free radical formation, inflammation, signaling pathways, platelet glycoproteins and nitric oxide. Chapters in the third section address functional endpoints used in evaluating cardiac drugs such as atrial and ventricular arrhythmias, expression systems and screening technologies used in ion channel drug discovery, molecular diversity of ion channels in the mouse heart as well as therapeutic approaches to development of drugs that provide delayed protection of the myocardium. Chapters in the fourth section deal with clinical aspects of cardiac drug development, including gene therapy, gender differences, pharmacometrics and angiogenesis therapy. Each chapter provides introductory information on relevant physiology, pharmacology, and pathophysiology needed to understand the topic.
Assessment:This is an excellent book for researchers with an interest in cardiac pharmacology. Chapters address a broad spectrum of therapeutic areas and discuss appropriate molecular, biochemical, and electrophysiological in vitro as well as in vivo approaches used in the investigation of cardiovascular pharmacology. Moreover, the book addresses current clinical therapeutic trends in cardiovascular medicine.
Editorials
From The Critics
Reviewer: Thomas L. Pazdernik, PhD(University of Kansas Medical Center)Description: This is a specialty book written by experts in the field of cardiac drug development as a contribution to the Methods in Pharmacology and Toxicology series.
Purpose: The purpose of this volume is to integrate basic and clinical cardiac pharmacology into one book that brings together both classical and molecular aspects in the development of drugs that affect the cardiovascular system.
Audience: This book provides a comprehensive overview of many advanced procedures in cardiac pharmacology that should be useful for graduate students and academic scientists as well as researchers in the pharmaceutical and biotechnology drug industries.
Features: The first section is an introductory overview of cardiac drug development from animal models to clinical trials written by the volume editor. The second section has chapters that deal with novel molecular targets as candidates for drug development, including oxygen free radical formation, inflammation, signaling pathways, platelet glycoproteins and nitric oxide. Chapters in the third section address functional endpoints used in evaluating cardiac drugs such as atrial and ventricular arrhythmias, expression systems and screening technologies used in ion channel drug discovery, molecular diversity of ion channels in the mouse heart as well as therapeutic approaches to development of drugs that provide delayed protection of the myocardium. Chapters in the fourth section deal with clinical aspects of cardiac drug development, including gene therapy, gender differences, pharmacometrics and angiogenesis therapy. Each chapter provides introductory information on relevant physiology, pharmacology, and pathophysiology needed to understand the topic.
Assessment: This is an excellent book for researchers with an interest in cardiac pharmacology. Chapters address a broad spectrum of therapeutic areas and discuss appropriate molecular, biochemical, and electrophysiological in vitro as well as in vivo approaches used in the investigation of cardiovascular pharmacology. Moreover, the book addresses current clinical therapeutic trends in cardiovascular medicine.
4 Stars! from Doody